Navigation Links
Regado Biosciences to Present at the Needham & Company's 10th Annual Healthcare Conference in New York City
Date:3/30/2011

BASKING RIDGE, N.J., March 30, 2011 /PRNewswire/ -- Regado Biosciences, a privately held company pioneering the development of antithrombotic aptamers with active control agents, announced that David J. Mazzo, PhD, President and CEO, will be presenting at the Needham & Company's 10th Annual Healthcare Conference at the New York Palace Hotel in New York City on Wednesday, April 6, 2011 at 11:20 a.m. EDT.  The presentation will include an overview of the Company's pipeline with emphasis on the lead development program, the innovative anticoagulant system REG1, including a summary of the REG1 phase 2b trial (RADAR) results.

ABOUT REGADO BIOSCIENCES

Regado Biosciences, Inc. is a private biopharmaceutical company pioneering a new therapeutic technology with the creation and development of proprietary controllable aptamer drug systems.  Each system comprises a nuclease-stabilized RNA aptamer, the therapeutic effect of which can be reversed partially or completely in real time by its specific and complementary oligonucleotide active control agent.  This technology is being applied to injectable antithrombotics (including anticoagulants and antiplatelet agents) in the acute and sub-acute care cardiovascular setting, a multi-billion dollar world-wide market in need of drugs with improved safety profiles and a greater degree of therapeutic control.  The products in Regado's pipeline are designed to act as optimized antithrombotics, uniquely concomitantly minimizing the risk of ischemia and bleeding, and, by allowing patient specific tuning of the desired therapeutic effect, providing a safe and unique approach to personalized medicine.

ABOUT REG1, REG2 and REG3  

Regado's lead program, the anticoagulant system REG1, consists of two parenteral agents both administered by IV bolus, the first being a potent highly selective Factor IXa inhibitor (pegnivacogin, a.k.a. RB006) and the second being its compleme
'/>"/>

SOURCE Regado Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
2. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
3. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
4. Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
5. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
6. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
7. Regado Biosciences Releases Positive Phase 2a Data for the Reversible Anticoagulant System REG1 at the European Society of Cardiology Congress In Barcelona, Spain
8. Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 17, 2009
9. Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009
10. Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference, 59th Annual Scientific Session, in Atlanta, Georgia on March 15, 2010
11. Regado Biosciences to Present at the 2010 Wells Fargo Healthcare Conference on June 24, 2010 in Boston, Massachusetts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... -- Former NASA scientist Tamim Hamid was ... discussed Theradome™, the first portable and wearable OTC hair ... firsthand how, via laser technology, Theradome™ offers individuals a ... not require surgery or medication.  "The ... the hair follicle, which is where the stem cells ...
(Date:5/4/2015)... May 4, 2015 PAREXEL International Corporation (NASDAQ: ... the UBS Healthcare Conference on Monday, May 18, 2015, in ... and Chief Financial Officer will be making a presentation on ... A live webcast of the presentation will be available ... in the Upcoming Events portion of the main page, ...
(Date:5/4/2015)... , May 4, 2015 Rogne Bioscience, ... psoriasis, today announced that preclinical and mechanism of action ... the Society of Investigative Dermatology (SID) Annual Meeting being ... Atlanta, Georgia . Logo - ... the development of RON2315, a novel, low MW (<1700 ...
Breaking Medicine Technology:FOX News Features Theradome as the Take-Home Solution to Tackle Baldness 2PAREXEL International to Present at UBS Healthcare Conference 2Rogne Bioscience to Present Data from Topical Biologic Psoriasis Program at Upcoming SID Annual Meeting 2015 2
... , POINT RICHMOND, Calif., Nov. 12 Transcept Pharmaceuticals, ... focused on the development and commercialization of proprietary products ... financial results for the three and nine months ended ... that on October 28, 2009, the FDA issued a ...
... / -- New research findings presented today ... International Conference in New York show promise in ... alternative medicine (CAM) using traditional research methods. Susan ... and Clinics of Minnesota (Children,s), presented findings on ...
Cached Medicine Technology:Transcept Pharmaceuticals Reports Third Quarter 2009 Financial Results 2Transcept Pharmaceuticals Reports Third Quarter 2009 Financial Results 3Transcept Pharmaceuticals Reports Third Quarter 2009 Financial Results 4Transcept Pharmaceuticals Reports Third Quarter 2009 Financial Results 5Transcept Pharmaceuticals Reports Third Quarter 2009 Financial Results 6Transcept Pharmaceuticals Reports Third Quarter 2009 Financial Results 7Transcept Pharmaceuticals Reports Third Quarter 2009 Financial Results 8Transcept Pharmaceuticals Reports Third Quarter 2009 Financial Results 9Transcept Pharmaceuticals Reports Third Quarter 2009 Financial Results 10Transcept Pharmaceuticals Reports Third Quarter 2009 Financial Results 11Transcept Pharmaceuticals Reports Third Quarter 2009 Financial Results 12New Research Shows Promise in Using Traditional Research Methods to Assess Efficacy of Complementary Therapies 2
(Date:5/4/2015)... 05, 2015 The National Association ... Betancourt as a 2015-2016 inductee into the NAPW ... with this prestigious distinction for leadership in business. NAPW ... women, boasting more than 700,000 members and over 200 ... with this important honor," said NAPW President Star Jones. ...
(Date:5/4/2015)... Every Friday afternoon at A Forever ... Southwest Michigan, patients and staff gather in the common ... rehabilitation program and to gain encouragement and inspiration in ... One by one, those patients who have completed their ... certificates and to share a bit about their journey ...
(Date:5/4/2015)... Montreal, CANADA (PRWEB) May 04, 2015 ... development of innovative proofreading technologies, today announced that ... #438 at the Music City Center, in Nashville ... Proofware is the world's first true all-in-one we-based ... everyone involved in the security of their brand ...
(Date:5/4/2015)... City, MO (PRWEB) May 04, 2015 ... vice president and chief physician executive, and William C. ... have received and accepted personal invitations from the Secretary ... National Security Forum (NSF) at the Air War College, ... is to expose influential citizens to senior U.S. and ...
(Date:5/4/2015)... Milton Hershey School® has named J. ... the Year, recognizing his commitment to pediatric cancer research ... for MHS students. , “Dr. Graves is a tremendous ... are provided a top-notch education, a nurturing environment, and ... Pete Gurt ’85, president of MHS. “He is applying ...
Breaking Medicine News(10 mins):Health News:National Association of Professional Women Inducts Gloria Betancourt, Receptionist at Consulate Health Care, into its 2015-2016 VIP Woman of the Year Circle 2Health News:A Forever Recovery Celebrates New Victories in Overcoming Addiction With Weekly Graduation 2Health News:Global Vision to Spotlight Proofware at INFO*FLEX 2015 2Health News:Saint Luke’s Health System Leadership Selected to Attend National Security Forum 2Health News:Milton Hershey School Names 2015 Alumnus of the Year 2
... Enjoy Broad Choice of,Prescription Drugs, WASHINGTON, Jan. 31 ... statement on new budget,figures that report the cost of ... years than was estimated last summer:, "Part D ... drugs. New budget documents show that the overall,projected cost ...
... 2008. As part of its ongoing efforts to do ... and a cure for Parkinson,s disease, The Michael J. ... $3 million in total funding to four industry teams ... the clinic. The awards were granted under MJFF,s Therapeutics ...
... Schering-Plough,Corporation (NYSE: SGP ) today reported ... received an A-1 recommendation(1) (highest,rating) for the ... risk patients in the latest Treatment of ... Society of America (IDSA),released this month. The ...
... Jan. 31 Cardinal Health, a,global provider of products ... care, today announced the resignation of Matthew D.,Walter from ... quarterly dividend., "We want to thank Matt for ... John B. McCoy, chairman of the Nominating and,Governance Committee. ...
... Jan. 31 National opinion leaders will,convene in ... latest data,guidelines, practical applications, and strategies for the ... to make the,meeting highly interactive., The Summit ... credits sponsored,by The Dannemiller Educational Foundation, and the ...
... a gene that is the key switch that allows ... Much like students in a kindergarten class lining up ... identified as Smarcd3, must align correctly with two other ... as myogenesis, said principal investigator Monte Westerfield, a professor ...
Cached Medicine News:Health News:Michael J. Fox Foundation awards up to $3 million to industry teams 2Health News:Michael J. Fox Foundation awards up to $3 million to industry teams 3Health News:New IDSA Clinical Practice Guidelines Recommend NOXAFIL(R) (Posaconazole) for Antifungal Prophylaxis in Certain High-Risk Patients 2Health News:New IDSA Clinical Practice Guidelines Recommend NOXAFIL(R) (Posaconazole) for Antifungal Prophylaxis in Certain High-Risk Patients 3Health News:New IDSA Clinical Practice Guidelines Recommend NOXAFIL(R) (Posaconazole) for Antifungal Prophylaxis in Certain High-Risk Patients 4Health News:New IDSA Clinical Practice Guidelines Recommend NOXAFIL(R) (Posaconazole) for Antifungal Prophylaxis in Certain High-Risk Patients 5Health News:New IDSA Clinical Practice Guidelines Recommend NOXAFIL(R) (Posaconazole) for Antifungal Prophylaxis in Certain High-Risk Patients 6Health News:Cardinal Health Announces Resignation of Director; Declares Regular Quarterly Dividend 2Health News:Dannemiller Memorial Education Foundation and GR MedEd, Inc. Announce Oncology Summit: From Discovery to Delivery 2Health News:Dannemiller Memorial Education Foundation and GR MedEd, Inc. Announce Oncology Summit: From Discovery to Delivery 3Health News:Oregon researchers find trigger gene for muscle development 2
... medication nebulizer achieves optimum lung penetration for ... range is 1.04-1.10 µ at 6-8 LPM. ... outlet., ,As the world leader in ... the assurance of proven technology by offering ...
... breakthrough continuous low-flow nebulizer performance. Patented ... technology allows for optimal medication and ... Heliox). OMNI~NEB takes on severe asthma, ... and critical care situations. Configure with ...
... offer a spill-proof design and effective output, ... angle. All medical nebulizers are free-standing for ... configurations are available., ,All Portex® medication ... medication nebulizers feature consistently fine misting and ...
... a spill-proof design and effective output, even ... All medical nebulizers are free-standing for easy ... are available., ,All Portex® medication nebulizer ... nebulizers feature consistently fine misting and the ...
Medicine Products: